Bibliography
- Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006;33(4):336-44
- Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006;33(4):323-30
- Matull WR, Pereira SP, O'Donohue JW. Biochemical markers of acute pancreatitis. J Clin Pathol 2006;59(4):340-4
- Smotkin J, Tenner S. Laboratory diagnostic tests in acute pancreatitis. J Clin Gastroenterol 2002;34(4):459-62
- Sternby B, O'Brien JF, Zinsmeister AR, Di Magno EP. What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study. Mayo Clin Proc 1996;71(12):1138-44
- Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5(5):262-9
- Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 2010;12:e1
- Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214(3):829-35
- Martin JH, Deacon CF, Gorrell MD, Prins JB. Incretin-based therapies-review of the physiology, pharmacology and emerging clinical experience. Intern Med J 2011;41(4):299-307
- Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124712.htm
- Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1):150-6
- Available from: http://www.safeguard-diabetes.org [Accessed 30 November 2012]
- AMY-P alpha-Amylase EPS Pancreatic (Cobas® Roche Diagnostics), scheda tecnica. 2011
- LIPC Lipasi colorimetric (Cobas® Roche Diagnostics), scheda tecnica. 2011
- Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680
- Singh S, Chang HY, Richards TM, et al. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173(7):534-9
- Shimmings A. Onglyza safety concerns prompt Dear Healthcare Professional letters. Scrip 2012;3592:6
- Girgis CM, Champion BL. Acute pancreatitis in a patient receiving vildagliptin. Endocr Pract 2011;1-6
- WHO. Pharmaceuticals. Newsletter 2012;1:16-18
- Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58(7):1604-15
- Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008;358(18):1969-70
- Garber A, Henry R, Ratner R, LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
- Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res 2005;15(1):72-7
- Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61(5):1250-62
- FDA “Information for Healthcare Professionals – Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). 2009. Available from: www.hhs.gov
- AIFA, Nota Informativa Importante Marzo. 2012. Available from: www.agenziafarmaco.it [Accessed 09 March 2012]